EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and validation of a nomogram for a prognostic model for resected pancreatic ductal adenocarcinoma

Tian-Liang Song, Fan Zhang, Chong Zhang, Hui-Juan Cheng, Ewetse Paul Maswikiti, Cheng-Yang Ji, Hao Chen, Fu-Tian Tang, Wen-Zhi Guo, Wen-Long Zhai, Yu-Min Li

Hepatobiliary & Pancreatic Diseases International · 2025

DOI: 10.1016/j.hbpd.2025.04.005 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Hepatobiliary & Pancreatic Diseases International, 2025. Verfasst von Tian-Liang Song und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China; Gansu Province Key Laboratory of Environmental Oncology, L…. Hauptthemen laut MEDLINE: Nomograms, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Pancreatectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Lanzhou University, Gansu Education Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor. Surgical resection is the most promising therapeutic strategy for PDAC, and how to improve the survival rate remains a vital key point. This study aimed to establish and validate a nomogram for predicting the prognosis of resected PDAC. METHODS: A total of 174 patients with PDAC who underwent surgical resection at Lanzhou University Second Hospital and the First Affiliated Hospital of Zhengzhou University from January 2012 to July 2022 were enrolled. The clinicopathological characteristics and survival data were analyzed by R software (version 4.1.3). Univariate and multivariate Cox regression analyses were used to analyze the effects of clinicopathological characteristics on overall survival (OS). RESULTS: Multivariate Cox regression showed that carbohydrate antigen 19-9 (CA19-9) ≥ 476 U/mL, carbohydrate antigen 125 (CA125) ≥ 32 U/mL, fasting blood glucose (FBG) < 6.86 mmol/L, aspartate aminotransferase (AST) ≥ 107 U/L, positive surgical margin, and more than 4 cycles of postoperative chemotherapy were independent prognostic factors for OS. Patients were divided into the high-risk and low-risk groups based on the median risk score calculated by multivariate Cox regression analysis. Kaplan-Meier survival curves revealed that the 5-year survival rates of the high-risk and low-risk groups in the training cohort were 5.8% and 24.3%, respectively, and those in the validation cohort were 0 and 19.0%, respectively (P < 0.05). Receiver operating characteristic (ROC) curve analysis revealed that area under the ROC curve (AUC) of the risk score in the training set and the validation set were 0.855 and 0.838, respectively. The C-indexes of the nomogram in the training set and validation set were 0.788 (95% CI: 0.745-0.831) and 0.773 (95% CI: 0.718-0.828), respectively. CONCLUSIONS: We developed a nomogram that predicts OS in patients with resected PDAC, and the validation results showed that the nomogram model had a strong predictive ability. Particularly, FBG < 6.86 mmol/L and more than 4 cycles of postoperative chemotherapy can predict better OS of PDAC after surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NomogramsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsPancreatectomyHumansFemaleMaleMiddle AgedAgedRetrospective StudiesRisk FactorsCA-19-9 AntigenPrognosisRisk AssessmentPredictive Value of TestsReproducibility of ResultsAdultTreatment OutcomeChina

Stichwörter der Autor:innen

NomogramPancreatic cancerPrognostic factorsSurgerySurvival rate

Substanzen

CA-19-9 Antigen

Autor:innen und Institutionen

  • Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China; Gansu Province Key Laboratory of Environmental Oncology, Lanzhou 730030, China.
  • Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
  • Gansu Province Key Laboratory of Environmental Oncology, Lanzhou 730030, China.
  • The Second Medical School of Lanzhou University, Lanzhou 730030, China.
  • Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Electronic address: Fcczhaiwl@zzu.edu.cn.
  • Gansu Province Key Laboratory of Environmental Oncology, Lanzhou 730030, China; Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China. Electronic address: liym@lzu.edu.cn.

Förderung

  • Fundamental Research Funds for the Central Universities
  • Lanzhou University
  • Gansu Education Department
  • Natural Science Foundation of Gansu Province

Zitieren

APA

Song, T. L., Zhang, F., Zhang, C., Cheng, H. J., Maswikiti, E. P., Ji, C. Y., Chen, H., Tang, F. T., Guo, W. Z., Zhai, W. L., & Li, Y. M. (2025). Development and validation of a nomogram for a prognostic model for resected pancreatic ductal adenocarcinoma. Hepatobiliary & Pancreatic Diseases International. https://doi.org/10.1016/j.hbpd.2025.04.005

Vancouver

Song TL, Zhang F, Zhang C, Cheng HJ, Maswikiti EP, Ji CY, et al. Development and validation of a nomogram for a prognostic model for resected pancreatic ductal adenocarcinoma. Hepatobiliary & Pancreatic Diseases International. 2025. doi:10.1016/j.hbpd.2025.04.005

BibTeX
@article{Song2025,
  author = {Song, Tian-Liang and Zhang, Fan and Zhang, Chong and Cheng, Hui-Juan and Maswikiti, Ewetse Paul and Ji, Cheng-Yang and Chen, Hao and Tang, Fu-Tian and Guo, Wen-Zhi and Zhai, Wen-Long and Li, Yu-Min},
  title = {Development and validation of a nomogram for a prognostic model for resected pancreatic ductal adenocarcinoma},
  journal = {Hepatobiliary & Pancreatic Diseases International},
  year = {2025},
  doi = {10.1016/j.hbpd.2025.04.005}
}
Kostenlos starten →